• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

New Data From Two Large Studies Reinforce Effectiveness of Dual Pathway Inhibition (DPI) with XARELTO ® (rivaroxaban) Plus Aspirin in Patients with Coronary Artery Disease (CAD) and/or Peripheral Artery Disease (PAD)
RARITAN, N.J., May 23, 2022 – Findings from the XARELTO® (rivaroxaban) Phase 3 COMPASS Long-Term Open Label Extension (LTOLE) study and the XARELTO® in Combination with Acetylsalicylic Acid (XATOA) registry have been published in the European Society of Cardiology’s (ESC) European Heart Journal, Cardiovascular Pharmacotherapy. Additionally, the XATOA registry was presented at the American Congress of Cardiology’s 71st Annual Scientific Session (ACC.22). These studies provide further evidence supporting the role of dual pathway inhibition (DPI) with the XARELTO® vascular dose (2.5 mg twice daily plus aspirin 100 mg...
Source: Johnson and Johnson - May 23, 2022 Category: Pharmaceuticals Source Type: news

Landmark Phase 3 VOYAGER PAD Study of XARELTO ® (rivaroxaban) Plus Aspirin Shows Significant Benefit in Patients with Symptomatic Peripheral Artery Disease (PAD) after Lower-Extremity Revascularization
RARITAN, NJ, March 28, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the VOYAGER PAD study met its primary efficacy and principal safety endpoints, demonstrating the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily) plus aspirin (100 mg once daily) was superior to aspirin alone in reducing the risk of major adverse limb and cardiovascular (CV) events by 15 percent in patients with symptomatic peripheral artery disease (PAD) after lower-extremity revascularization, with similar rates of TIMI[1] major bleeding. VOYAGER PAD is the only study to show a significant benefit using...
Source: Johnson and Johnson - March 28, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen Submits Application to U.S. FDA for New Indication to Expand Use of XARELTO ® (rivaroxaban) in Patients with Peripheral Artery Disease
RARITAN, NJ, October 26, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for a new indication to expand the use of XARELTO® (rivaroxaban) in patients with peripheral artery disease (PAD). If approved, this new indication for the XARELTO® vascular dose (2.5 mg twice daily plus aspirin 75-100 mg once daily) would include reducing the risk of major thrombotic vascular events such as heart attack, stroke and amputation in patients after recent lower-extremity revascularization, a c...
Source: Johnson and Johnson - October 26, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Real-World Study Confirms Benefit of XARELTO ® (rivaroxaban) for Secondary Prevention of Venous Thromboembolism in Cancer Patients
TITUSVILLE, NJ, December 9, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced observational data from eight years of clinical practice showing that the oral Factor Xa inhibitor XARELTO® (rivaroxaban) is associated with comparable effectiveness and safety to the Factor Xa inhibitor apixaban for the treatment of cancer-associated thromboembolism (CAT) in a broad cohort of patients with various cancer types. Patients with CAT are at a higher risk of venous thromboembolism (VTE), which is the second-leading cause of death in people with cancer.1Data from the Observational Study in Cancer-A...
Source: Johnson and Johnson - December 9, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news

Vascular Complications in Maternal Care
According to the Centers for Disease Control and Prevention, heart disease and stroke are 2 of the 3 leading causes of death in women across the lifetime. Most women do not expect to experience heart disease or stroke during pregnancy. However, in a recent study in California, the American Heart Association (AHA) reported heart disease as the number 1 cause of pregnancy-related mortality.
Source: The Journal for Nurse Practitioners - March 20, 2014 Category: Nursing Authors: Deedra H. Harrington, Laurie Kinchen Tags: Diagnostic Tips Source Type: research

Approaches in Prehospital Sepsis Screening
Discussion In the United States, sepsis is one of the leading causes of death, which requires timely identification and proper treatment (CDC, 2019; Guerra et al., 2020; Polito et al., 2015). Based upon a review of literature conducted from 2014 to 2018, the primary investigators could locate five prehospital EMS screening tools to assist EMS providers in identifying at-risk sepsis patients. The researchers explored how the modified SIRS and qSOFA scoring systems were used in hospital settings in addition to these five prehospital EMS screening tools. The Bas 90-30-90, Guerra, PRESEP, PRESS, and Robson tools have ove...
Source: JEMS Patient Care - January 5, 2021 Category: Emergency Medicine Authors: JEMS Staff Tags: Exclusives Patient Care EMS EMT Paramedic Prehospital Sepsis Source Type: news

In the Raw: To Cook or Not to Cook?
Imagine never again savoring the smell of baking cakes or charbroiled steak. Could you? Why would you? Yet some people worldwide are turning away not only from meat and processed food, but also from cooking. Welcome to the raw food diet. As the Standard American Diet becomes more fat-laden, sugar-sated, and processed, the prevalence of metabolic disorders, obesity, type 2 diabetes, and cardiovascular disease (CVD) are soaring. According to the Centers for Disease Control and Prevention (CDC), obesity now affects nearly 35 percent of the population of the United States, over 29 million people have been diagnosed with t...
Source: Healthy Living - The Huffington Post - August 4, 2016 Category: Consumer Health News Source Type: news

Massachusetts Defies U.S. Trend With Binge Drinkers Drinking Less, Study Shows
(CNN) — Adults in the United States who binge drink are consuming even more alcohol per binging episode, according to a new study published Thursday by the US Centers for Disease Control and Prevention. Researchers analyzed data from the Behavioral Risk Factor Surveillance System over a six-year period and discovered that the annual number of binge drinks among adults who reported excessive drinking jumped on average from 472 in 2011 to 529 in 2017. That’s a 12% increase. In 2017, the number of binge drinks per year among adult binge drinkers ranged from 320 per year in Massachusetts to 1,219 in Wyoming. The nu...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - January 18, 2020 Category: Consumer Health News Authors: Health – CBS Boston Tags: Boston News Health Syndicated CBSN Boston Binge Drinking CNN Massachusetts News Source Type: news

What the Science Says About the Health Benefits of Vitamins and Supplements
From multivitamins and melatonin to fiber and fish oil, Americans who are trying to boost their health and immunity have a plethora of supplements to choose from. An estimated 58% of U.S. adults ages 20 and over take dietary supplements, according to the U.S. Centers for Disease Control and Prevention, and the supplement industry is valued at more than $30 billion a year. Supplement use has been growing rapidly over the past few decades along with the wellness industry. “The popular belief is that a supplement is going to be helpful for promoting health,” says Fang Fang Zhang, a professor at Tufts University&rs...
Source: TIME: Health - April 28, 2022 Category: Consumer Health News Authors: Sandeep Ravindran Tags: Uncategorized Diet & Nutrition healthscienceclimate Source Type: news

Evidence-Based Contraception: Common Questions and Answers
Am Fam Physician. 2022 Sep;106(3):251-259.ABSTRACTPrimary care clinicians are uniquely situated to reduce unintended pregnancy in the context of a patient's medical comorbidities, social circumstance, and gender identity. New evidence regarding contraception use has emerged in recent years. The copper intrauterine device is the most effective option for emergency contraception, with similar effectiveness found for the levonorgestrel-releasing intrauterine system, 52 mg, and both offer extended future contraception. Ulipristal given within 120 hours after unprotected intercourse is the most effective oral emergency contrace...
Source: American Family Physician - September 20, 2022 Category: Primary Care Authors: Scott L Paradise Corinne A Landis David A Klein Source Type: research

Pages: 1  2  3